[go: up one dir, main page]

CN113754768B - 结合cd39的抗体及其用途 - Google Patents

结合cd39的抗体及其用途 Download PDF

Info

Publication number
CN113754768B
CN113754768B CN202110808944.1A CN202110808944A CN113754768B CN 113754768 B CN113754768 B CN 113754768B CN 202110808944 A CN202110808944 A CN 202110808944A CN 113754768 B CN113754768 B CN 113754768B
Authority
CN
China
Prior art keywords
antibody
seq
antigen
amino acid
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN202110808944.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN113754768A (zh
Inventor
S·查佩尔
A·莱克
M·沃伦
A·杜拉克
E·德沃雷厄克斯
P·M·霍兰
T·扎伊迪
M·罗施
B·普林茨
N·P·尼尔森
S·达斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surface Oncology Inc
Original Assignee
Surface Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surface Oncology Inc filed Critical Surface Oncology Inc
Publication of CN113754768A publication Critical patent/CN113754768A/zh
Application granted granted Critical
Publication of CN113754768B publication Critical patent/CN113754768B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
CN202110808944.1A 2018-03-14 2019-03-13 结合cd39的抗体及其用途 Expired - Fee Related CN113754768B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862642938P 2018-03-14 2018-03-14
US62/642,938 2018-03-14
US201962803235P 2019-02-08 2019-02-08
US62/803,235 2019-02-08
CN201980018508.5A CN112262155A (zh) 2018-03-14 2019-03-13 结合cd39的抗体及其用途
PCT/US2019/022108 WO2019178269A2 (fr) 2018-03-14 2019-03-13 Anticorps qui se lient à cd39 et leurs utilisations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980018508.5A Division CN112262155A (zh) 2018-03-14 2019-03-13 结合cd39的抗体及其用途

Publications (2)

Publication Number Publication Date
CN113754768A CN113754768A (zh) 2021-12-07
CN113754768B true CN113754768B (zh) 2023-01-06

Family

ID=67903871

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110808944.1A Expired - Fee Related CN113754768B (zh) 2018-03-14 2019-03-13 结合cd39的抗体及其用途
CN201980018508.5A Pending CN112262155A (zh) 2018-03-14 2019-03-13 结合cd39的抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980018508.5A Pending CN112262155A (zh) 2018-03-14 2019-03-13 结合cd39的抗体及其用途

Country Status (14)

Country Link
US (4) US10738128B2 (fr)
EP (2) EP3765524A4 (fr)
JP (3) JP7037218B2 (fr)
KR (4) KR102411489B1 (fr)
CN (2) CN113754768B (fr)
AU (3) AU2019235842B2 (fr)
BR (2) BR112020018480B1 (fr)
CA (1) CA3092635A1 (fr)
IL (3) IL301295A (fr)
MA (1) MA52022A (fr)
MX (3) MX391028B (fr)
NZ (2) NZ767596A (fr)
SG (1) SG11202008390SA (fr)
WO (1) WO2019178269A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
SG11202000820PA (en) 2017-07-31 2020-02-27 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
EP3710052A1 (fr) * 2017-11-15 2020-09-23 Innate Pharma Potentialisation de l'effet de libération d'atp
CN113754768B (zh) 2018-03-14 2023-01-06 表面肿瘤学公司 结合cd39的抗体及其用途
AU2020225542A1 (en) * 2019-02-21 2021-09-30 Trishula Therapeutics, Inc. Combination therapy involving anti-CD39 antibodies and anti-PD-1 or anti-PD-L1 antibodies
AU2020351122A1 (en) 2019-09-16 2022-02-17 Surface Oncology, Inc. Anti-CD39 antibody compositions and methods
TW202521984A (zh) 2019-09-25 2025-06-01 美商表面腫瘤學有限責任公司 抗ｉｌ－２７抗體及其用途
US12391756B2 (en) * 2019-11-05 2025-08-19 Jacobio Pharmaceuticals Co., Ltd. Binding molecule specific for CD39 and use thereof
CN113372444A (zh) * 2020-03-09 2021-09-10 北京恩瑞尼生物科技股份有限公司 通过抑制胞外核苷酸酶和抗体-介导靶向吞噬预防或逆转t-细胞衰竭的组合物与用途
CA3202988A1 (fr) * 2020-11-27 2022-06-02 Elpiscience (Suzhou) Biopharma, Ltd. Nouvelles molecules conjuguees ciblant cd39 et tgfbeta
KR20240005809A (ko) 2021-05-07 2024-01-12 서피스 온콜로지, 엘엘씨 항-il-27 항체 및 이의 용도
WO2022237723A1 (fr) * 2021-05-12 2022-11-17 杭州邦顺制药有限公司 Anticorps anti-cd39, son procédé de préparation et son utilisation
US20230036592A1 (en) 2021-06-03 2023-02-02 Surface Oncology, Inc. Methods of treating cancer with an anti-cd39 antibody and pembrolizumab
CN113777309A (zh) * 2021-09-07 2021-12-10 复旦大学附属肿瘤医院 自身抗体在制备胰腺导管腺癌诊断试剂盒中的应用
CN115975030B (zh) * 2021-09-30 2023-09-26 杭州邦顺制药有限公司 抗cd39抗体-药物偶联物及其用途
WO2023164872A1 (fr) * 2022-03-03 2023-09-07 Arcus Biosciences, Inc. Anticorps anti-cd39 et leur utilisation
WO2023165561A1 (fr) 2022-03-03 2023-09-07 Arcus Biosciences, Inc. Anticorps anti-cd39 et leur utilisation
US20250228938A1 (en) * 2022-03-08 2025-07-17 Whitehead Institute For Biomedical Research The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer
JP2025512384A (ja) 2022-04-13 2025-04-17 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
CN118063609A (zh) * 2022-11-23 2024-05-24 广东菲鹏制药股份有限公司 抗cd39抗体及其应用
KR20250112761A (ko) 2022-12-01 2025-07-24 이나뜨 파르마 에스.에이. 항-cd39 항체를 포함하는 암의 신보조 치료를 위한 조성물 및 방법
TW202509069A (zh) 2023-05-04 2025-03-01 美商諾瓦森塔股份有限公司 抗cd161抗體及其使用方法
KR20250023773A (ko) 2023-08-10 2025-02-18 현대자동차주식회사 유니버설 구동 장치
KR20250041420A (ko) 2023-09-18 2025-03-25 현대자동차주식회사 링키지 구조 및 이를 이용한 유니버설 구동장치
WO2025137640A1 (fr) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Inhibiteurs azaspiro de wrn

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017157948A1 (fr) * 2016-03-14 2017-09-21 Innate Pharma Anticorps anti-cd39

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (fr) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipides en phase aqueuse
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (fr) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
JP3771253B2 (ja) 1988-09-02 2006-04-26 ダイアックス コープ． 新規な結合タンパク質の生成と選択
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (fr) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production d'anticorps utilisant des librairies de genes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5658727A (en) 1991-04-10 1997-08-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
AU1736495A (en) 1994-01-31 1995-08-15 Trustees Of Boston University Polyclonal antibody libraries
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
AU3117697A (en) 1996-05-06 1997-11-26 Uab Research Foundation, The Radiolabeled fusion toxins for cancer therapy
EP1068241B1 (fr) 1998-04-02 2007-10-10 Genentech, Inc. Variants d'anticorps et fragments de ceux-ci
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
EP1257632B1 (fr) 2000-02-24 2007-09-12 Xcyte Therapies, Inc. Stimulation et concentration simultanees de cellules
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
AU2002361763A1 (en) 2001-12-17 2003-06-30 Beth Israel Deaconess Medical Center Method of reducing angiogenesis
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
CN117534755A (zh) 2005-05-09 2024-02-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SG2014010029A (en) 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
ES2437327T3 (es) 2007-06-18 2014-01-10 Merck Sharp & Dohme B.V. Anticuerpos para el receptor PD-1 humano de muerte programada
EP3124497B1 (fr) 2007-09-14 2020-04-15 Adimab, LLC Bibliothèques d'anticorps synthétiques conçus de façon rationnelle et leurs utilisations
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US20100303828A1 (en) * 2008-01-31 2010-12-02 INSERM Institut National de la Sante et de la Recherche Medicale) Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
KR20240093808A (ko) 2008-12-09 2024-06-24 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
EP2210891A1 (fr) 2009-01-26 2010-07-28 Domain Therapeutics Nouveaux ligands du récepteur de l'adénosine et leurs utilisations
HUE025704T2 (en) 2009-03-20 2016-04-28 Sigma Tau Ind Farmaceuti Oxidized triazolyl purine derivatives used as adenosine A2A receptor ligands and their use as medicaments
EP2504028A4 (fr) 2009-11-24 2014-04-09 Amplimmune Inc Inhibition simultanée de pd-l1/pd-l2
HRP20160636T1 (hr) 2010-02-05 2016-07-29 Heptares Therapeutics Limited Derivati 1,2,4-triazin-4-amina
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
US9044460B2 (en) 2010-05-04 2015-06-02 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (EGFR) and uses thereof
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
WO2012085132A1 (fr) 2010-12-22 2012-06-28 Orega Biotech Anticorps contre cd39 humain et utilisation de ceux-ci
SG11201402603WA (en) 2011-11-28 2014-06-27 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
SG11201407190TA (en) 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
ES2923641T3 (es) 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Inmunoglobulina con Fabs en tándem y usos de la misma
CA2936244A1 (fr) 2014-01-21 2015-07-30 Medimmune, Llc Compositions et procedes pour moduler et reorienter des reponses immunitaires
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
DK3129470T3 (da) 2014-04-07 2021-07-05 Novartis Ag Behandling af cancer ved anvendelse af anti-CD19-kimær antigenreceptor
WO2016073845A1 (fr) 2014-11-07 2016-05-12 Igenica Biotherapeutics, Inc. Anticorps anti-cd39 et utilisations
JP6847037B2 (ja) 2014-11-11 2021-03-24 メディミューン リミテッド 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
WO2016106159A1 (fr) 2014-12-22 2016-06-30 Enumeral Biomedical Holding, Inc. Anticorps anti-pd-1
KR20250075716A (ko) 2014-12-29 2025-05-28 노파르티스 아게 키메라 항원 수용체-발현 세포를 제조하는 방법
WO2017025918A1 (fr) 2015-08-11 2017-02-16 Novartis Ag 5-bromo -2,6-di- (1h-pyrazol-1-yl)pyrimidin-4-amine pour utilisation dans le traitement du cancer
WO2017152102A2 (fr) * 2016-03-04 2017-09-08 Alector Llc Anticorps anti-trem1 et leurs méthodes d'utilisation
US10793636B2 (en) 2016-07-11 2020-10-06 Corvus Pharmaceuticals, Inc. Anti-CD73 antibodies
SG11202000820PA (en) * 2017-07-31 2020-02-27 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
CN113754768B (zh) 2018-03-14 2023-01-06 表面肿瘤学公司 结合cd39的抗体及其用途
AU2020225542A1 (en) * 2019-02-21 2021-09-30 Trishula Therapeutics, Inc. Combination therapy involving anti-CD39 antibodies and anti-PD-1 or anti-PD-L1 antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017157948A1 (fr) * 2016-03-14 2017-09-21 Innate Pharma Anticorps anti-cd39

Also Published As

Publication number Publication date
MX2022003718A (es) 2022-04-26
MX2020009568A (es) 2022-03-28
KR102411490B1 (ko) 2022-06-22
US20210363268A1 (en) 2021-11-25
EP4043496A1 (fr) 2022-08-17
KR102495666B1 (ko) 2023-02-06
NZ767596A (en) 2022-01-28
WO2019178269A3 (fr) 2019-10-17
NZ782442A (en) 2022-01-28
IL277242B2 (en) 2023-07-01
KR20220088802A (ko) 2022-06-28
JP7037218B2 (ja) 2022-03-16
JP2022020862A (ja) 2022-02-01
KR20200131272A (ko) 2020-11-23
BR112020018480B1 (pt) 2022-09-27
AU2019235842A1 (en) 2020-09-24
AU2021269448A1 (en) 2022-01-06
AU2021269448B2 (en) 2022-02-03
AU2022202656A1 (en) 2022-05-12
US20190284295A1 (en) 2019-09-19
US20200399394A1 (en) 2020-12-24
KR102411489B1 (ko) 2022-06-23
KR20210143933A (ko) 2021-11-29
EP3765524A4 (fr) 2021-12-22
IL287565B1 (en) 2023-04-01
JP2021518103A (ja) 2021-08-02
MA52022A (fr) 2021-01-20
US10738128B2 (en) 2020-08-11
IL277242B1 (en) 2023-03-01
US10793637B2 (en) 2020-10-06
JP7068736B2 (ja) 2022-05-17
EP3765524A2 (fr) 2021-01-20
MX2021015518A (es) 2022-07-21
IL277242A (en) 2020-10-29
CN112262155A (zh) 2021-01-22
US20200277394A1 (en) 2020-09-03
WO2019178269A2 (fr) 2019-09-19
MX391028B (es) 2025-03-21
BR112020018480A2 (pt) 2020-12-22
BR122022000386B1 (pt) 2022-09-27
JP2022115879A (ja) 2022-08-09
AU2019235842B2 (en) 2022-02-03
IL287565B2 (en) 2023-08-01
CN113754768A (zh) 2021-12-07
MX394121B (es) 2025-03-24
IL287565A (en) 2021-12-01
IL301295A (en) 2023-05-01
CA3092635A1 (fr) 2019-09-19
KR20230020023A (ko) 2023-02-09
SG11202008390SA (en) 2020-09-29

Similar Documents

Publication Publication Date Title
CN113754768B (zh) 结合cd39的抗体及其用途
CN112512571B (zh) 抗il-27抗体及其用途
US20220259299A1 (en) Anti-il-27 antibodies and uses thereof
KR20220066346A (ko) 항-il-27 항체 및 이의 용도
HK40072004A (en) Antibodies that bind cd39 and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230106